ConductScience.org, home

Paper26765645

Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

Dumitriu B and 20 others. Lancet Haematol, 2016. Cited by 45 papers, by iCite.

Cite this record

ConductScience Library. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Papers, record 26765645. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26765645

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.
PubMed
Journal
Lancet Haematol
PubMed
Year
2016
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
45
iCite
Relative citation ratio, by iCite
1.58
iCite
Revised in PubMed
2025-05-29
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dumitriu BBogdan
2Ito SSawa
3Feng XXingmin
4Stephens NNicole
5Yunce MMuharrem
6Kajigaya SSachiko
7Melenhorst JJJoseph J
8Rios OOlga
9Scheinberg PPriscila
10Chinian FFariba
11Keyvanfar KKeyvan
12Battiwalla MMinoo
13Wu COColin O
14Maric IIrina
15Xi LLiqiang
16Raffeld MMark
17Muranski PPawel
18Townsley DMDanielle M
19Young NSNeal S
20Barrett AJAustin J

Source PubMed

See all 21 authorsDownload CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Antineoplastic AgentsMajor topic
Leukemia, Large Granular LymphocyticMajor topic
Aged
Alemtuzumab
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Prospective Studies
Remission Induction
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z99 CA999999Intramural NIH HHSUnited StatesZ99CA999999PubMedNIH RePORTER
ZICBC011079NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00345345Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte LeukemiaDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in26765647Alemtuzumab in T-cell large granular lymphocyte leukaemia.https://conductscience.org/library/papers/26765647

Source PubMed

Download CSV of comments and corrections

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117148582Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.Blood2007https://conductscience.org/library/papers/17148582PubMed
217045649T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.Leuk Res2007https://conductscience.org/library/papers/17045649PubMed
319597025
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
J Clin Oncol2009https://conductscience.org/library/papers/19597025PubMed
419794084Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.Haematologica2009https://conductscience.org/library/papers/19794084PubMed
520367569Large granular lymphocyte leukemia: natural history and response to treatment.Leuk Lymphoma2010https://conductscience.org/library/papers/20367569PubMed
620211489Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.Leuk Res2010https://conductscience.org/library/papers/20211489PubMed
721041705Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.J Clin Oncol2010https://conductscience.org/library/papers/21041705PubMed
821190991How I treat LGL leukemia.Blood2011https://conductscience.org/library/papers/21190991PubMed
921571962Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy.Am J Clin Pathol2011https://conductscience.org/library/papers/21571962PubMed
1021948296Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.Blood2011https://conductscience.org/library/papers/21948296PubMed
1123122652Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.Lancet2012https://conductscience.org/library/papers/23122652PubMed
1222859607STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.Blood2012https://conductscience.org/library/papers/22859607PubMed
1323122650Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.Lancet2012https://conductscience.org/library/papers/23122650PubMed
1422067384Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.Blood2012https://conductscience.org/library/papers/22067384PubMed
1516111536Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.Leuk Res2005https://conductscience.org/library/papers/16111536PubMed
1616193089Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.Leukemia2005https://conductscience.org/library/papers/16193089PubMed
1716795070T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.Cancer2006https://conductscience.org/library/papers/16795070PubMed
187920220Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.Leuk Lymphoma1994https://conductscience.org/library/papers/7920220PubMed
192317110Phenotypic and genotypic analysis of mononuclear cells from patients with Felty's syndrome.Ann Rheum Dis1990https://conductscience.org/library/papers/2317110PubMed
202403836Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study.Cancer1990https://conductscience.org/library/papers/2403836PubMed

See all 32 referencesDownload CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.

PMIDTitleJournalYearIn PapersSource
42977785Salvage therapy for immune-mediated bone marrow failure.Leukemia2026https://conductscience.org/library/papers/42977785PubMed
42706151[Chinese expert consensus on the diagnosis and treatment of large granular lymphocytic leukemia (2026)].Zhonghua Xue Ye Xue Za Zhi2026https://conductscience.org/library/papers/42706151PubMed
41899567How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas.Cancers (Basel)2026https://conductscience.org/library/papers/41899567PubMed
41580422CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.NPJ Breast Cancer2026https://conductscience.org/library/papers/41580422PubMed
40342876Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.Hemasphere2025https://conductscience.org/library/papers/40342876PubMed
40214729Alemtuzumab for haematological malignancies.Ann Hematol2025https://conductscience.org/library/papers/40214729PubMed
40147444KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia.Cell Rep Med2025https://conductscience.org/library/papers/40147444PubMed
39644019Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations.Hematology Am Soc Hematol Educ Program2024https://conductscience.org/library/papers/39644019PubMed
39540224Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia.Haematologica2025https://conductscience.org/library/papers/39540224PubMed
38610985Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment.Cancers (Basel)2024https://conductscience.org/library/papers/38610985PubMed
37658347Peripheral neuropathy associated with chronic lymphoproliferative disorders of natural killer cells (CLPD-NK): a case report and literature review.BMC Neurol2023https://conductscience.org/library/papers/37658347PubMed
36362180Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia.Int J Mol Sci2022https://conductscience.org/library/papers/36362180PubMed
35672859Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report.J Med Case Rep2022https://conductscience.org/library/papers/35672859PubMed
35411050Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia.Nat Commun2022https://conductscience.org/library/papers/35411050PubMed
35411048Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells.Nat Commun2022https://conductscience.org/library/papers/35411048PubMed
35223485T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?Front Oncol2022https://conductscience.org/library/papers/35223485PubMed
35212923Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment.Curr Oncol Rep2022https://conductscience.org/library/papers/35212923PubMed
35178350Toward a Better Classification System for NK-LGL Disorders.Front Oncol2022https://conductscience.org/library/papers/35178350PubMed
34685780Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options.Cells2021https://conductscience.org/library/papers/34685780PubMed
34503230Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease.Cancers (Basel)2021https://conductscience.org/library/papers/34503230PubMed

See all 26 cited byDownload CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ALEMTUZUMABCHEMBL1201587Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201587

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26765645

GET https://conductscience.org/api/papers/v1/26765645/authors?page=2